J P Morgan Chase & Co set a €85.00 ($101.19) price objective on Sanofi SA (EPA:SAN) in a research report sent to investors on Thursday. The firm currently has a neutral rating on the stock.

Several other analysts also recently commented on the stock. Jefferies Group LLC set a €92.00 ($109.52) target price on shares of Sanofi SA and gave the stock a neutral rating in a report on Monday, May 29th. Credit Suisse Group set a €95.00 ($113.10) target price on shares of Sanofi SA and gave the stock a buy rating in a report on Tuesday, July 4th. Kepler Capital Markets set a €89.00 ($105.95) target price on shares of Sanofi SA and gave the stock a buy rating in a report on Wednesday, July 26th. Goldman Sachs Group, Inc. (The) set a €82.00 ($97.62) price objective on shares of Sanofi SA and gave the company a neutral rating in a report on Wednesday, May 24th. Finally, Berenberg Bank set a €97.00 ($115.48) price objective on shares of Sanofi SA and gave the company a neutral rating in a report on Saturday, May 20th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of €87.88 ($104.61).

Shares of Sanofi SA (EPA:SAN) opened at 81.37 on Thursday. Sanofi SA has a 1-year low of €24.55 and a 1-year high of €82.67. The company has a 50 day moving average of €26.12 and a 200 day moving average of €25.99. The company has a market cap of €102.18 billion and a PE ratio of 11.35.

ILLEGAL ACTIVITY WARNING: “J P Morgan Chase & Co Reiterates €85.00 Price Target for Sanofi SA (SAN)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/09/17/j-p-morgan-chase-85-00-price-target-for-sanofi-sa-san.html.

Sanofi SA Company Profile

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Stock Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related stocks with our FREE daily email newsletter.